| [1] Endo I,Matsumoto T.Frontiers in Vitamin D;Basic Research and Clinical Application. Eldecalcitol : the effect on bone and calcium metabolism.Clin Calcium.2011;21(11):1687-1694.[2] Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism.Endocrinol Metab. 2004;5(2):60-65.[3] Thomas T.Intermittent parathyroid hormone therapy to increase bone formation .Joint Bone Spine.2006;73(3):262-269.[4] O’Brien CA. Control of RANKL gene expression. Bone.2010; 46(4):911-919.[5] Magno AL,Ward BK,Ratajczak T.The calcium-sensing receptor:a molecular perspective.Endocr Rev.2011;32(1): 23-30.[6] Fujita T, Meguro T, Fukuyama R, et al. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Check point of modulation by cyclic AMP. Biol Chem. 2002;277 (25):22191-22200.[7] Rashid G, Plotkin E, Klein O, et al.Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C. Renal Physiol.2009;296(1):60-66.[8] Swarthout JT,D'Alonzo RC,Selvamurugan N,et al.Parathyroid hormone-dependent signaling pathways regulating genes in bone cells.Gene.2002;282(1-2):11-17.[9] Kwok S, Qin L, Partridge NC, et al.Parathyroid hormone stimulation and PKA signaling of latent transforming growthfactor-beta binding protein-1(LTBP-1)mRNA expression in osteoblastic cells.Cell Biochem.2005;95(5): 1002-1011.[10] 王立童,周淳,陈元川.核结合因子的表达及其对骨细胞的作用研究[J].中国骨质疏松杂志,2008;14(12):914-917.[11] 鲍捷,王国祥.Wnt/β-连环蛋白对应力刺激的变化机制及其在骨代谢信号通路中调节作用[J].中国运动医学杂志, 2011,30(8): 795-781.[12] Hofbauer LC,Kuhne CA,Viereck V.The OPG/RANKL/RANK system in metabolic bone diseases.Musculoskelet Neuronal Interact.2004;4(3):268-275.[13] 万启龙,王强,李祖兵.PTH对骨代谢双重作用的研究进展[J].中国口腔颌面外科杂志,2011;9(4):343-346.[14] Tam CS, Heersche JN, Murray TM, et al.Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action:differential effects of intermittent and continuous administration. Endocrinology.1982;110(2): 506-512.[15] Poole KE,Reeve J.Parathyroid hormone a bone anabolic and catabolic agent. Current Opinion in Pharmacology.2005;5: 612-617.[16] Jilka RL, O'Brien CA, Bartell SM, et al. Continuous Elevation of PTH Increases the Number of Osteoblasts via Both Osteoclast-Dependent and Independent Mechanisms.Bone Miner Res.2010;25(11):2427-2437.[17] Holmen SL, Zylstra CR, Mukherjee A,et al.Essential role of beta-catena in postnatal bone acquisition.Biol Chem.2005; 280(22):21162-21168.[18] Suzuki A,Ozono K,Kubota T,et al.PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen syntheses kinase-3beta in osteoblastic Saros-2 cells.Cell Biochem.2008;104(1):304-317.[19] Rodda SJ,McMahon AP.Distinct roles for Hedgehog and canonical Wnt signaling in specification,differentiation and maintenance of osteoblast progenitors.Development. 2006; 133(16):3231-3244.[20] Shinoda Y, Kawaguchi H, Higashikawa A, et al.Mechanisms Underlying Catabolic and Anabolic Functions of Parathyroid Hormone on Bone by Combination of Culture Systems of Mouse Cells.Cell Biochem.2010;109(4):755-763.[21] Jacome-Galarza CE, Lee SK, Lorenzo JA,et al.Parathyroid Hormone Regulates the Distribution and Osteoclastogenic Potential of Hematopoietic Progenitors in the Bone Marrow.Bone Miner Res.2011;26(6):1207-1216.[22] Huang JC, Sakata T, Pfleger LL, et al.PTH Differentially Regulates Expression of RANKL and OPG.Bone Miner Res. 2004;19(2):235-244.[23] Zheng F, Liang H, Liu R, et al.Parathyroid hormone-related protein regulates osteoclast Inhibitory lectin expression via multiple signaling pathways in osteoblast-like cells.Endocrine. 2009;35(1):47-56.[24] Scott JP, Sale C, Greeves JP, et al.The Effect of Training Status on the Metabolic Response of Bone to an Acute Bout of Exhaustive Treadmill Running.Clin Endocrinol Metab.2010; 95(8):3918-3925.[25] Locklin RM,Khosla S,Turnr RT,et al.Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.Cell Biochem. 2003;89(1): 180-190.[26] Ma YL,Cain RL,Halladay DL.et al.Catabolic effects of continuous human PTH(1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001;142(9):4047-4054.[27] Galli C,Zella LA,Fretz JA,et al.Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear fac-tor-kappa B ligand gene reduces bone remodeling and increases bone mass.Endocrinology.2008;149(1):146-153.[28] Yasuda H,Shima N,Nakaqawa N.et al.Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.Proc Natl Acad.1998;95(7):3597-3602.[29] Kraus D, Jäger A, Abuduwali N, et al.Intermittent PTH(1–34)signals through protein kinase A to regulate osteoprotegerin production in human periodontal ligament cells in vitro.Clin Oral Investig.2011.[30] Lossdörfer S, Götz W, Jäger A. PTH(1- 34 )- induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells.Clin Oral Investig.2011;15(6):941– 952.[31] Komrakova M, Stuermer EK, Werner C, et al.Effect of human parathyroid hormone hPTH(1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats.Bone.2010;47(3):480-492. |
